{"#title":"Chlamydia Screening in Women (CHL)","#attached":{"library":["mqis\/reports"],"drupalSettings":{"mqis":{"measures":{"121162":{"xcomps":{"2024":"2024"},"ycomps":{"2024":{"0":"61.6","5":"65.5","10":"49.1"}},"complegend":{"0":"New England Medicaid Managed Care CY 2024","5":"National Medicaid Managed Care 75th Percentile CY 2024","10":"NH Commercial CY 2024"},"compdata":{"Comparison Rate":[{"name":"New England Medicaid Managed Care","data_source":"New England Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"2","notes":"","year":"2024","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"New England Medicaid Managed Care","data_source":"New England Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"2","notes":"","year":"2023","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"New England Medicaid Managed Care","data_source":"New England Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"2","notes":"","year":"2023","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"New England Medicaid Managed Care","data_source":"New England Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"2","notes":"","year":"2022","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"New England Medicaid Managed Care","data_source":"New England Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"2","notes":"","year":"2021","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"New England Medicaid Managed Care","data_source":"New England Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"2","notes":"","year":"2020","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"New England Medicaid Managed Care","data_source":"New England Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"2","notes":"","year":"2020","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"National Medicaid Managed Care 75th Percentile","data_source":"National Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"3","notes":"","year":"2024","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"National Medicaid Managed Care 75th Percentile","data_source":"National Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"3","notes":"","year":"2023","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"National Medicaid Managed Care 75th Percentile","data_source":"National Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"3","notes":"","year":"2023","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"National Medicaid Managed Care 75th Percentile","data_source":"National Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"3","notes":"","year":"2022","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"National Medicaid Managed Care 75th Percentile","data_source":"National Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"3","notes":"","year":"2021","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"National Medicaid Managed Care 75th Percentile","data_source":"National Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"3","notes":"","year":"2020","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"National Medicaid Managed Care 75th Percentile","data_source":"National Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"3","notes":"","year":"2020","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"NH Commercial","data_source":"NH Commercial","data_source_order":"14","notes":"","year":"2024","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"NH Commercial","data_source":"NH Commercial","data_source_order":"14","notes":"","year":"2023","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"NH Commercial","data_source":"NH Commercial","data_source_order":"14","notes":"","year":"2023","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"NH Commercial","data_source":"NH Commercial","data_source_order":"14","notes":"","year":"2022","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"NH Commercial","data_source":"NH Commercial","data_source_order":"14","notes":"","year":"2021","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"NH Commercial","data_source":"NH Commercial","data_source_order":"14","notes":"","year":"2020","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"NH Commercial","data_source":"NH Commercial","data_source_order":"14","notes":"","year":"2020","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"}]},"ymax":115,"comp_table":"\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
Chlamydia Screening in Women (CHL) - Comparators (Export<\/a>)<\/span><\/caption>\n \n \n
Original Order\n \n Sort descending\n <\/span>\n<\/span>\n<\/a><\/th>\n Measure ID<\/a><\/th>\n Measure Name<\/a><\/th>\n Comparator Name<\/a><\/th>\n Comparator Type<\/a><\/th>\n Year<\/a><\/th>\n Value<\/a><\/th>\n <\/tr>\n <\/thead>\n \n
0<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n New England Medicaid Managed Care CY 2024<\/td>\n Comparison Rate<\/td>\n 2024<\/td>\n \u2021<\/td>\n <\/tr>\n
1<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n New England Medicaid Managed Care CY 2023<\/td>\n Comparison Rate<\/td>\n 2023<\/td>\n \u2021<\/td>\n <\/tr>\n
2<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n New England Medicaid Managed Care CY 2022<\/td>\n Comparison Rate<\/td>\n 2022<\/td>\n \u2021<\/td>\n <\/tr>\n
3<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n New England Medicaid Managed Care CY 2021<\/td>\n Comparison Rate<\/td>\n 2021<\/td>\n \u2021<\/td>\n <\/tr>\n
4<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n New England Medicaid Managed Care CY 2020<\/td>\n Comparison Rate<\/td>\n 2020<\/td>\n \u2021<\/td>\n <\/tr>\n
5<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n National Medicaid Managed Care 75th Percentile CY 2024<\/td>\n Comparison Rate<\/td>\n 2024<\/td>\n \u2021<\/td>\n <\/tr>\n
6<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n National Medicaid Managed Care 75th Percentile CY 2023<\/td>\n Comparison Rate<\/td>\n 2023<\/td>\n \u2021<\/td>\n <\/tr>\n
7<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n National Medicaid Managed Care 75th Percentile CY 2022<\/td>\n Comparison Rate<\/td>\n 2022<\/td>\n \u2021<\/td>\n <\/tr>\n
8<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n National Medicaid Managed Care 75th Percentile CY 2021<\/td>\n Comparison Rate<\/td>\n 2021<\/td>\n \u2021<\/td>\n <\/tr>\n
9<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n National Medicaid Managed Care 75th Percentile CY 2020<\/td>\n Comparison Rate<\/td>\n 2020<\/td>\n \u2021<\/td>\n <\/tr>\n
10<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n NH Commercial CY 2024<\/td>\n Comparison Rate<\/td>\n 2024<\/td>\n 49.1<\/td>\n <\/tr>\n
11<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n NH Commercial CY 2023<\/td>\n Comparison Rate<\/td>\n 2023<\/td>\n 49.0<\/td>\n <\/tr>\n
12<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n NH Commercial CY 2022<\/td>\n Comparison Rate<\/td>\n 2022<\/td>\n 49.4<\/td>\n <\/tr>\n
13<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n NH Commercial CY 2021<\/td>\n Comparison Rate<\/td>\n 2021<\/td>\n 49.0<\/td>\n <\/tr>\n
14<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n NH Commercial CY 2020<\/td>\n Comparison Rate<\/td>\n 2020<\/td>\n 52.0<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n","xseries":{"2014":"2014","2015":"2015","2016":"2016","2017":"2017","2018":"2018","2019":"2019","2020":"2020","2021":"2021","2022":"2022","2023":"2023","2024":"2024"},"yseries":{"Chlamydia Screening in Women (CHL)":{"2014":"40.8","2015":"42.9","2016":"45.6","2017":"46.6","2018":"46.5","2019":"50.1","2020":"46.5","2021":"48.3","2022":"48.6","2023":"47.6","2024":"46.8"}},"trendlegend":{"Chlamydia Screening in Women (CHL)":"Total (All Subgroups)"},"numerators":{"Chlamydia Screening in Women (CHL)":[1227,2293,1670,1639,1661,2741,3259,4181,4263,2300,2436]},"denominators":{"Chlamydia Screening in Women (CHL)":[3009,5348,3660,3516,3571,5471,7016,8655,8773,4828,5205]},"timeperiods":{"t_2014-01-01_2014-12-31":{"start":"1388552400","end":"1420002000"},"t_2015-01-01_2015-12-31":{"start":"1420088400","end":"1451538000"},"t_2016-01-01_2016-12-31":{"start":"1451624400","end":"1483160400"},"t_2017-01-01_2017-12-31":{"start":"1483246800","end":"1514696400"},"t_2018-01-01_2018-12-31":{"start":"1514782800","end":"1546232400"},"t_2019-01-01_2019-12-31":{"start":"1546318800","end":"1577768400"},"t_2020-01-01_2020-12-31":{"start":"1577854800","end":"1609390800"},"t_2021-01-01_2021-12-31":{"start":"1609477200","end":"1640926800"},"t_2022-01-01_2022-12-31":{"start":"1641013200","end":"1672462800"},"t_2023-01-01_2023-12-31":{"start":"1672549200","end":"1703998800"},"t_2024-01-01_2024-12-31":{"start":"1704085200","end":"1735621200"}},"data_elements":[{"data_element_id":"263685","identifier":"HEDIS_CHL.A.1620_NUM","measure_id":"121163","type":"1","tech_definition":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","class":"1","uploader_user_id":"51","last_modified":"1705430487","spec_id":"844","data_element_class_name":"Numerator"},{"data_element_id":"263686","identifier":"HEDIS_CHL.A.1620_DEN","measure_id":"121163","type":"1","tech_definition":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","class":"2","uploader_user_id":"51","last_modified":"1705430502","spec_id":"844","data_element_class_name":"Denominator"},{"data_element_id":"263687","identifier":"HEDIS_CHL.A.1620_RATE","measure_id":"121163","type":"1","tech_definition":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","class":"3","uploader_user_id":"51","last_modified":"1705430517","spec_id":"844","data_element_class_name":"Rate"},{"data_element_id":"263688","identifier":"HEDIS_CHL.A.1620_LCI","measure_id":"121163","type":"1","tech_definition":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","class":"4","uploader_user_id":"51","last_modified":"1705430530","spec_id":"844","data_element_class_name":"Lower Confidence Interval"},{"data_element_id":"263689","identifier":"HEDIS_CHL.A.1620_UCI","measure_id":"121163","type":"1","tech_definition":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","class":"5","uploader_user_id":"51","last_modified":"1705430546","spec_id":"844","data_element_class_name":"Upper Confidence Interval"}],"data_table":"\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
Chlamydia Screening in Women (CHL) (Export<\/a>)<\/span><\/caption>\n \n \n
Time Period<\/th>\n Measure Name<\/th>\n Measure Numerator<\/th>\n Measure Denominator<\/th>\n Measure Rate<\/th>\n Confidence Interval<\/th>\n <\/tr>\n <\/thead>\n \n
2014-01-01 - 2014-12-31<\/td>\n Total (All Subgroups)<\/td>\n 1,227<\/td>\n 3,009<\/td>\n 40.8%<\/td>\n 39.0 - 42.6<\/td>\n <\/tr>\n
2015-01-01 - 2015-12-31<\/td>\n Total (All Subgroups)<\/td>\n 2,293<\/td>\n 5,348<\/td>\n 42.9%<\/td>\n 41.6 - 44.2<\/td>\n <\/tr>\n
2016-01-01 - 2016-12-31<\/td>\n Total (All Subgroups)<\/td>\n 1,670<\/td>\n 3,660<\/td>\n 45.6%<\/td>\n 44.0 - 47.2<\/td>\n <\/tr>\n
2017-01-01 - 2017-12-31<\/td>\n Total (All Subgroups)<\/td>\n 1,639<\/td>\n 3,516<\/td>\n 46.6%<\/td>\n 45.0 - 48.2<\/td>\n <\/tr>\n
2018-01-01 - 2018-12-31<\/td>\n Total (All Subgroups)<\/td>\n 1,661<\/td>\n 3,571<\/td>\n 46.5%<\/td>\n 44.9 - 48.1<\/td>\n <\/tr>\n
2019-01-01 - 2019-12-31<\/td>\n Total (All Subgroups)<\/td>\n 2,741<\/td>\n 5,471<\/td>\n 50.1%<\/td>\n 48.8 - 51.4<\/td>\n <\/tr>\n
2020-01-01 - 2020-12-31<\/td>\n Total (All Subgroups)<\/td>\n 3,259<\/td>\n 7,016<\/td>\n 46.5%<\/td>\n 45.3 - 47.7<\/td>\n <\/tr>\n
2021-01-01 - 2021-12-31<\/td>\n Total (All Subgroups)<\/td>\n 4,181<\/td>\n 8,655<\/td>\n 48.3%<\/td>\n 47.2 - 49.4<\/td>\n <\/tr>\n
2022-01-01 - 2022-12-31<\/td>\n Total (All Subgroups)<\/td>\n 4,263<\/td>\n 8,773<\/td>\n 48.6%<\/td>\n 47.6 - 49.6<\/td>\n <\/tr>\n
2023-01-01 - 2023-12-31<\/td>\n Total (All Subgroups)<\/td>\n 2,300<\/td>\n 4,828<\/td>\n 47.6%<\/td>\n 46.2 - 49.0<\/td>\n <\/tr>\n
2024-01-01 - 2024-12-31<\/td>\n Total (All Subgroups)<\/td>\n 2,436<\/td>\n 5,205<\/td>\n 46.8%<\/td>\n 45.4 - 48.2<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n","suppressed":false,"orgs":{"MCM: AmeriHealth Caritas NH":12,"MCM: NH Healthy Families":1,"MCM: Well Sense":3,"MCM: Meridian":2},"qualifiers":{"2014":[],"2015":[],"2016":[],"2017":[],"2018":[],"2019":[],"2020":[],"2021":[],"2022":[],"2023":[],"2024":[],"":["The aggregated values do not include data for all organizations. Customize this report by organization for details."]},"verifieds":{"2014":{"3":false,"1":false},"2015":{"1":false,"3":false},"2016":{"1":false,"3":false},"2017":{"3":false,"1":false},"2018":{"1":false,"3":false},"2019":{"3":false,"1":false},"2020":{"12":false,"1":false,"3":false},"2021":{"3":false,"1":false,"12":false},"2022":{"3":false,"1":false,"12":false},"2023":{"12":false,"1":false,"3":false},"2024":{"3":false,"1":false,"12":false}},"measure":{"measure_id":"121162","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)","description":"

HEDIS\u00ae Measurement Description: The percentage of women 16-24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year.<\/p>","tech_definition":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","relevance":"

This measure captures the percent of sexually active females 16-24 years of age who had at least one test for chlamydia during the past year. Chlamydia is the most common sexually transmitted disease in the United States, and may lead to an increased risk of pelvic infections, infertility, and complications during pregnancy. The Centers for Disease Control and Prevention recommends that all sexually active women < 25 years of age and high-risk women > 25 years of age be tested for chlamydia at least annually. A low or falling rate may indicate women are not being routinely screened and may be at a greater risk for an undetected Chlamydia infection. This measure is calculated based on the number of sexually active females 16-24 years of age, who received at least one chlamydia test during the past year, divided by the total eligible population, reported as a percentage.<\/p>","tech_definition_owner_id":"2302","steward_id":"3","data_source":"6","rate_source":"1","rate_formula":"c:1|\/|c:2|*|100","parent_measure_id":"0","uploader_user_id":"51","submission_frequency":"4","reporting_period_min":"1483246800","reporting_period_max":"4102376400","last_modified":"1751904675","spec_id":"844","rate_precision":"1","rate_type":"1","steward_measure_id":"CHL","requirement_source":"Exhibit O","optional_exclusions":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","comments":"","subpopulation":"0","summary_of_changes":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","eligible_population":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","period_length":"1","submission_due_date_lag":"7","lag_unit":"Months","use_case":"1","short_name":"Chlamydia Screening in Women","retired":"","period_length_multiplier":"1","submission_frequency_multiplier":"1","acknowledgements":"

HEDIS\u00ae is a registered trademark of the National Committee for Quality Assurance (NCQA).<\/p>","retired_reason":"","replaced_by":"","definitions":"","summarize":"0","rate_weighted":"0","frequency_name":"Years","period_length_name":"Years","data_source_name":"Administrative","rate_type_name":"Percent","yaxis_label":"","machine_name":"chlamydia-screening-in-women-chl-1","show_mean":"0","attr_links":"","period_info":{"name":"Year","format":"Y","label_format":"Y","diff_name":"year","diff_format":"y","diff_mult":"1","maxperiods":16}},"aggregated":true,"init":false,"org_abbrevs":{"14":"FFS (CTS)","8":"MPAP","10":"FFS-PAP","1":"NHHF","3":"WS","12":"ACNH","16":"NEDD","4":"MFFS","11":"DHHS","13":"FFS (OC)","2":"Meri"},"ci":{"Chlamydia Screening in Women (CHL)":[{"lower":"39.0","upper":"42.6"},{"lower":"41.6","upper":"44.2"},{"lower":"44.0","upper":"47.2"},{"lower":"45.0","upper":"48.2"},{"lower":"44.9","upper":"48.1"},{"lower":"48.8","upper":"51.4"},{"lower":"45.3","upper":"47.7"},{"lower":"47.2","upper":"49.4"},{"lower":"47.6","upper":"49.6"},{"lower":"46.2","upper":"49.0"},{"lower":"45.4","upper":"48.2"}]},"statuses":{"Chlamydia Screening in Women (CHL)":{"2014":{"6":"Published"},"2015":{"6":"Published"},"2016":{"6":"Published"},"2017":{"6":"Published"},"2018":{"6":"Published"},"2019":{"6":"Published"},"2020":{"6":"Published"},"2021":{"6":"Published"},"2022":{"6":"Published"},"2023":{"6":"Published"},"2024":{"6":"Published"}}},"comptypes":{"2024":{"0":"1","5":"1","10":"1"}},"comppref":{"2024":{"0":">=","5":">=","10":">="}},"compsources":{"2024":{"0":"New England Medicaid Managed Care, Quality Compass, NCQA","5":"National Medicaid Managed Care, Quality Compass, NCQA","10":"NH Commercial"}},"compsuppress":{"2024":{"0":"1","5":"1","10":"0"}},"compmeasures":{"2024":[{"id":"117335","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"117335","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"117335","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null],"2023":[null,{"id":"121162","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"121162","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"121162","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null],"2022":[null,null,{"id":"117080","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"117080","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"117080","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null],"2021":[null,null,null,{"id":"114608","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"114608","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"114608","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null],"2020":[null,null,null,null,{"id":"111909","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"111909","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"111909","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"}]}}},"template_options":{"template":"allinfo","trend_graph":true,"trend_type":"line","confidence":true,"comparator_graph":true,"data_tables":true,"submitted_data":true,"comparator_data":true,"data_source":true,"relevance":true,"topics":true,"description":true,"definitions":true,"tech_def":true,"data_elements":true,"eligible":true,"summary":true,"comparator_details":true},"filename":"Chlamydia_Screening_in_Women_(CHL)","fixed_denom":2,"comp_goal":3,"generated":"Oct 16 2025 at 15:25","suppression_note":"Data has been suppressed due to small sample size."}}},"#theme":"mqis_measure_report_enhanced_template","#measures":{"121162":{"xcomps":{"2024":"2024"},"ycomps":{"2024":{"0":"61.6","5":"65.5","10":"49.1"}},"complegend":{"0":"New England Medicaid Managed Care CY 2024","5":"National Medicaid Managed Care 75th Percentile CY 2024","10":"NH Commercial CY 2024"},"compdata":{"Comparison Rate":[{"name":"New England Medicaid Managed Care","data_source":"New England Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"2","notes":"","year":"2024","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"New England Medicaid Managed Care","data_source":"New England Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"2","notes":"","year":"2023","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"New England Medicaid Managed Care","data_source":"New England Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"2","notes":"","year":"2023","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"New England Medicaid Managed Care","data_source":"New England Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"2","notes":"","year":"2022","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"New England Medicaid Managed Care","data_source":"New England Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"2","notes":"","year":"2021","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"New England Medicaid Managed Care","data_source":"New England Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"2","notes":"","year":"2020","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"New England Medicaid Managed Care","data_source":"New England Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"2","notes":"","year":"2020","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"National Medicaid Managed Care 75th Percentile","data_source":"National Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"3","notes":"","year":"2024","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"National Medicaid Managed Care 75th Percentile","data_source":"National Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"3","notes":"","year":"2023","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"National Medicaid Managed Care 75th Percentile","data_source":"National Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"3","notes":"","year":"2023","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"National Medicaid Managed Care 75th Percentile","data_source":"National Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"3","notes":"","year":"2022","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"National Medicaid Managed Care 75th Percentile","data_source":"National Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"3","notes":"","year":"2021","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"National Medicaid Managed Care 75th Percentile","data_source":"National Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"3","notes":"","year":"2020","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"National Medicaid Managed Care 75th Percentile","data_source":"National Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"3","notes":"","year":"2020","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"NH Commercial","data_source":"NH Commercial","data_source_order":"14","notes":"","year":"2024","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"NH Commercial","data_source":"NH Commercial","data_source_order":"14","notes":"","year":"2023","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"NH Commercial","data_source":"NH Commercial","data_source_order":"14","notes":"","year":"2023","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"NH Commercial","data_source":"NH Commercial","data_source_order":"14","notes":"","year":"2022","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"NH Commercial","data_source":"NH Commercial","data_source_order":"14","notes":"","year":"2021","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"NH Commercial","data_source":"NH Commercial","data_source_order":"14","notes":"","year":"2020","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"},{"name":"NH Commercial","data_source":"NH Commercial","data_source_order":"14","notes":"","year":"2020","year_type":"CY","measure_name":"Chlamydia Screening in Women (CHL)"}]},"ymax":115,"comp_table":"\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
Chlamydia Screening in Women (CHL) - Comparators (Export<\/a>)<\/span><\/caption>\n \n \n
Original Order\n \n Sort descending\n <\/span>\n<\/span>\n<\/a><\/th>\n Measure ID<\/a><\/th>\n Measure Name<\/a><\/th>\n Comparator Name<\/a><\/th>\n Comparator Type<\/a><\/th>\n Year<\/a><\/th>\n Value<\/a><\/th>\n <\/tr>\n <\/thead>\n \n
0<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n New England Medicaid Managed Care CY 2024<\/td>\n Comparison Rate<\/td>\n 2024<\/td>\n \u2021<\/td>\n <\/tr>\n
1<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n New England Medicaid Managed Care CY 2023<\/td>\n Comparison Rate<\/td>\n 2023<\/td>\n \u2021<\/td>\n <\/tr>\n
2<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n New England Medicaid Managed Care CY 2022<\/td>\n Comparison Rate<\/td>\n 2022<\/td>\n \u2021<\/td>\n <\/tr>\n
3<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n New England Medicaid Managed Care CY 2021<\/td>\n Comparison Rate<\/td>\n 2021<\/td>\n \u2021<\/td>\n <\/tr>\n
4<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n New England Medicaid Managed Care CY 2020<\/td>\n Comparison Rate<\/td>\n 2020<\/td>\n \u2021<\/td>\n <\/tr>\n
5<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n National Medicaid Managed Care 75th Percentile CY 2024<\/td>\n Comparison Rate<\/td>\n 2024<\/td>\n \u2021<\/td>\n <\/tr>\n
6<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n National Medicaid Managed Care 75th Percentile CY 2023<\/td>\n Comparison Rate<\/td>\n 2023<\/td>\n \u2021<\/td>\n <\/tr>\n
7<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n National Medicaid Managed Care 75th Percentile CY 2022<\/td>\n Comparison Rate<\/td>\n 2022<\/td>\n \u2021<\/td>\n <\/tr>\n
8<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n National Medicaid Managed Care 75th Percentile CY 2021<\/td>\n Comparison Rate<\/td>\n 2021<\/td>\n \u2021<\/td>\n <\/tr>\n
9<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n National Medicaid Managed Care 75th Percentile CY 2020<\/td>\n Comparison Rate<\/td>\n 2020<\/td>\n \u2021<\/td>\n <\/tr>\n
10<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n NH Commercial CY 2024<\/td>\n Comparison Rate<\/td>\n 2024<\/td>\n 49.1<\/td>\n <\/tr>\n
11<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n NH Commercial CY 2023<\/td>\n Comparison Rate<\/td>\n 2023<\/td>\n 49.0<\/td>\n <\/tr>\n
12<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n NH Commercial CY 2022<\/td>\n Comparison Rate<\/td>\n 2022<\/td>\n 49.4<\/td>\n <\/tr>\n
13<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n NH Commercial CY 2021<\/td>\n Comparison Rate<\/td>\n 2021<\/td>\n 49.0<\/td>\n <\/tr>\n
14<\/td>\n HEDIS_CHL.A<\/td>\n Chlamydia Screening in Women (CHL)<\/td>\n NH Commercial CY 2020<\/td>\n Comparison Rate<\/td>\n 2020<\/td>\n 52.0<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n","xseries":{"2014":"2014","2015":"2015","2016":"2016","2017":"2017","2018":"2018","2019":"2019","2020":"2020","2021":"2021","2022":"2022","2023":"2023","2024":"2024"},"yseries":{"Chlamydia Screening in Women (CHL)":{"2014":"40.8","2015":"42.9","2016":"45.6","2017":"46.6","2018":"46.5","2019":"50.1","2020":"46.5","2021":"48.3","2022":"48.6","2023":"47.6","2024":"46.8"}},"trendlegend":{"Chlamydia Screening in Women (CHL)":"Total (All Subgroups)"},"numerators":{"Chlamydia Screening in Women (CHL)":[1227,2293,1670,1639,1661,2741,3259,4181,4263,2300,2436]},"denominators":{"Chlamydia Screening in Women (CHL)":[3009,5348,3660,3516,3571,5471,7016,8655,8773,4828,5205]},"timeperiods":{"t_2014-01-01_2014-12-31":{"start":"1388552400","end":"1420002000"},"t_2015-01-01_2015-12-31":{"start":"1420088400","end":"1451538000"},"t_2016-01-01_2016-12-31":{"start":"1451624400","end":"1483160400"},"t_2017-01-01_2017-12-31":{"start":"1483246800","end":"1514696400"},"t_2018-01-01_2018-12-31":{"start":"1514782800","end":"1546232400"},"t_2019-01-01_2019-12-31":{"start":"1546318800","end":"1577768400"},"t_2020-01-01_2020-12-31":{"start":"1577854800","end":"1609390800"},"t_2021-01-01_2021-12-31":{"start":"1609477200","end":"1640926800"},"t_2022-01-01_2022-12-31":{"start":"1641013200","end":"1672462800"},"t_2023-01-01_2023-12-31":{"start":"1672549200","end":"1703998800"},"t_2024-01-01_2024-12-31":{"start":"1704085200","end":"1735621200"}},"data_elements":[{"data_element_id":"263685","identifier":"HEDIS_CHL.A.1620_NUM","measure_id":"121163","type":"1","tech_definition":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","class":"1","uploader_user_id":"51","last_modified":"1705430487","spec_id":"844","data_element_class_name":"Numerator"},{"data_element_id":"263686","identifier":"HEDIS_CHL.A.1620_DEN","measure_id":"121163","type":"1","tech_definition":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","class":"2","uploader_user_id":"51","last_modified":"1705430502","spec_id":"844","data_element_class_name":"Denominator"},{"data_element_id":"263687","identifier":"HEDIS_CHL.A.1620_RATE","measure_id":"121163","type":"1","tech_definition":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","class":"3","uploader_user_id":"51","last_modified":"1705430517","spec_id":"844","data_element_class_name":"Rate"},{"data_element_id":"263688","identifier":"HEDIS_CHL.A.1620_LCI","measure_id":"121163","type":"1","tech_definition":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","class":"4","uploader_user_id":"51","last_modified":"1705430530","spec_id":"844","data_element_class_name":"Lower Confidence Interval"},{"data_element_id":"263689","identifier":"HEDIS_CHL.A.1620_UCI","measure_id":"121163","type":"1","tech_definition":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","class":"5","uploader_user_id":"51","last_modified":"1705430546","spec_id":"844","data_element_class_name":"Upper Confidence Interval"}],"data_table":"\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
Chlamydia Screening in Women (CHL) (Export<\/a>)<\/span><\/caption>\n \n \n
Time Period<\/th>\n Measure Name<\/th>\n Measure Numerator<\/th>\n Measure Denominator<\/th>\n Measure Rate<\/th>\n Confidence Interval<\/th>\n <\/tr>\n <\/thead>\n \n
2014-01-01 - 2014-12-31<\/td>\n Total (All Subgroups)<\/td>\n 1,227<\/td>\n 3,009<\/td>\n 40.8%<\/td>\n 39.0 - 42.6<\/td>\n <\/tr>\n
2015-01-01 - 2015-12-31<\/td>\n Total (All Subgroups)<\/td>\n 2,293<\/td>\n 5,348<\/td>\n 42.9%<\/td>\n 41.6 - 44.2<\/td>\n <\/tr>\n
2016-01-01 - 2016-12-31<\/td>\n Total (All Subgroups)<\/td>\n 1,670<\/td>\n 3,660<\/td>\n 45.6%<\/td>\n 44.0 - 47.2<\/td>\n <\/tr>\n
2017-01-01 - 2017-12-31<\/td>\n Total (All Subgroups)<\/td>\n 1,639<\/td>\n 3,516<\/td>\n 46.6%<\/td>\n 45.0 - 48.2<\/td>\n <\/tr>\n
2018-01-01 - 2018-12-31<\/td>\n Total (All Subgroups)<\/td>\n 1,661<\/td>\n 3,571<\/td>\n 46.5%<\/td>\n 44.9 - 48.1<\/td>\n <\/tr>\n
2019-01-01 - 2019-12-31<\/td>\n Total (All Subgroups)<\/td>\n 2,741<\/td>\n 5,471<\/td>\n 50.1%<\/td>\n 48.8 - 51.4<\/td>\n <\/tr>\n
2020-01-01 - 2020-12-31<\/td>\n Total (All Subgroups)<\/td>\n 3,259<\/td>\n 7,016<\/td>\n 46.5%<\/td>\n 45.3 - 47.7<\/td>\n <\/tr>\n
2021-01-01 - 2021-12-31<\/td>\n Total (All Subgroups)<\/td>\n 4,181<\/td>\n 8,655<\/td>\n 48.3%<\/td>\n 47.2 - 49.4<\/td>\n <\/tr>\n
2022-01-01 - 2022-12-31<\/td>\n Total (All Subgroups)<\/td>\n 4,263<\/td>\n 8,773<\/td>\n 48.6%<\/td>\n 47.6 - 49.6<\/td>\n <\/tr>\n
2023-01-01 - 2023-12-31<\/td>\n Total (All Subgroups)<\/td>\n 2,300<\/td>\n 4,828<\/td>\n 47.6%<\/td>\n 46.2 - 49.0<\/td>\n <\/tr>\n
2024-01-01 - 2024-12-31<\/td>\n Total (All Subgroups)<\/td>\n 2,436<\/td>\n 5,205<\/td>\n 46.8%<\/td>\n 45.4 - 48.2<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n","suppressed":false,"orgs":{"MCM: AmeriHealth Caritas NH":12,"MCM: NH Healthy Families":1,"MCM: Well Sense":3,"MCM: Meridian":2},"qualifiers":{"2014":[],"2015":[],"2016":[],"2017":[],"2018":[],"2019":[],"2020":[],"2021":[],"2022":[],"2023":[],"2024":[],"":["The aggregated values do not include data for all organizations. Customize this report by organization for details."]},"verifieds":{"2014":{"3":false,"1":false},"2015":{"1":false,"3":false},"2016":{"1":false,"3":false},"2017":{"3":false,"1":false},"2018":{"1":false,"3":false},"2019":{"3":false,"1":false},"2020":{"12":false,"1":false,"3":false},"2021":{"3":false,"1":false,"12":false},"2022":{"3":false,"1":false,"12":false},"2023":{"12":false,"1":false,"3":false},"2024":{"3":false,"1":false,"12":false}},"measure":{"measure_id":"121162","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)","description":"

HEDIS\u00ae Measurement Description: The percentage of women 16-24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year.<\/p>","tech_definition":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","relevance":"

This measure captures the percent of sexually active females 16-24 years of age who had at least one test for chlamydia during the past year. Chlamydia is the most common sexually transmitted disease in the United States, and may lead to an increased risk of pelvic infections, infertility, and complications during pregnancy. The Centers for Disease Control and Prevention recommends that all sexually active women < 25 years of age and high-risk women > 25 years of age be tested for chlamydia at least annually. A low or falling rate may indicate women are not being routinely screened and may be at a greater risk for an undetected Chlamydia infection. This measure is calculated based on the number of sexually active females 16-24 years of age, who received at least one chlamydia test during the past year, divided by the total eligible population, reported as a percentage.<\/p>","tech_definition_owner_id":"2302","steward_id":"3","data_source":"6","rate_source":"1","rate_formula":"c:1|\/|c:2|*|100","parent_measure_id":"0","uploader_user_id":"51","submission_frequency":"4","reporting_period_min":"1483246800","reporting_period_max":"4102376400","last_modified":"1751904675","spec_id":"844","rate_precision":"1","rate_type":"1","steward_measure_id":"CHL","requirement_source":"Exhibit O","optional_exclusions":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","comments":"","subpopulation":"0","summary_of_changes":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","eligible_population":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","period_length":"1","submission_due_date_lag":"7","lag_unit":"Months","use_case":"1","short_name":"Chlamydia Screening in Women","retired":"","period_length_multiplier":"1","submission_frequency_multiplier":"1","acknowledgements":"

HEDIS\u00ae is a registered trademark of the National Committee for Quality Assurance (NCQA).<\/p>","retired_reason":"","replaced_by":"","definitions":"","summarize":"0","rate_weighted":"0","frequency_name":"Years","period_length_name":"Years","data_source_name":"Administrative","rate_type_name":"Percent","yaxis_label":"","machine_name":"chlamydia-screening-in-women-chl-1","show_mean":"0","attr_links":"","period_info":{"name":"Year","format":"Y","label_format":"Y","diff_name":"year","diff_format":"y","diff_mult":"1","maxperiods":16}},"aggregated":true,"init":false,"org_abbrevs":{"14":"FFS (CTS)","8":"MPAP","10":"FFS-PAP","1":"NHHF","3":"WS","12":"ACNH","16":"NEDD","4":"MFFS","11":"DHHS","13":"FFS (OC)","2":"Meri"},"ci":{"Chlamydia Screening in Women (CHL)":[{"lower":"39.0","upper":"42.6"},{"lower":"41.6","upper":"44.2"},{"lower":"44.0","upper":"47.2"},{"lower":"45.0","upper":"48.2"},{"lower":"44.9","upper":"48.1"},{"lower":"48.8","upper":"51.4"},{"lower":"45.3","upper":"47.7"},{"lower":"47.2","upper":"49.4"},{"lower":"47.6","upper":"49.6"},{"lower":"46.2","upper":"49.0"},{"lower":"45.4","upper":"48.2"}]},"statuses":{"Chlamydia Screening in Women (CHL)":{"2014":{"6":"Published"},"2015":{"6":"Published"},"2016":{"6":"Published"},"2017":{"6":"Published"},"2018":{"6":"Published"},"2019":{"6":"Published"},"2020":{"6":"Published"},"2021":{"6":"Published"},"2022":{"6":"Published"},"2023":{"6":"Published"},"2024":{"6":"Published"}}},"comptypes":{"2024":{"0":"1","5":"1","10":"1"}},"comppref":{"2024":{"0":">=","5":">=","10":">="}},"compsources":{"2024":{"0":"New England Medicaid Managed Care, Quality Compass, NCQA","5":"National Medicaid Managed Care, Quality Compass, NCQA","10":"NH Commercial"}},"compsuppress":{"2024":{"0":"1","5":"1","10":"0"}},"compmeasures":{"2024":[{"id":"117335","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"117335","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"117335","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null],"2023":[null,{"id":"121162","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"121162","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"121162","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null],"2022":[null,null,{"id":"117080","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"117080","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"117080","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null],"2021":[null,null,null,{"id":"114608","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"114608","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"114608","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null],"2020":[null,null,null,null,{"id":"111909","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"111909","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"},null,null,null,null,{"id":"111909","identifier":"HEDIS_CHL.A","name":"Chlamydia Screening in Women (CHL)"}]}}},"#template_options":{"template":"allinfo","trend_graph":true,"trend_type":"line","confidence":true,"comparator_graph":true,"data_tables":true,"submitted_data":true,"comparator_data":true,"data_source":true,"relevance":true,"topics":true,"description":true,"definitions":true,"tech_def":true,"data_elements":true,"eligible":true,"summary":true,"comparator_details":true},"#filename":"Chlamydia_Screening_in_Women_(CHL)","#description":"","#header_links":"","#footer":"

Master Export<\/a> (all data for the reported measures as a csv file)<\/span><\/p>

Report Details<\/h3>

Generated on Oct 16 2025 at 15:25
Measures: Chlamydia Screening in Women (CHL)
Max Time Periods: 16
Organizations: All (aggregated)
Data Publish Statuses: Published<\/p>

Data Qualifiers:<\/p>